Sajan Eapen, MD
Nephrology · Houston, TXNPI 1811134281
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations.
Across 123 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$440
- AstraZeneca$253
- OPKO Pharmaceuticals, LLC$211
- Otsuka America Pharmaceutical, Inc.$209
- Akebia Therapeutics Inc$174
- Amgen$158
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,55593%
- Education$1967%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 30 | $440 |
| AstraZeneca | 8 | $253 |
| OPKO Pharmaceuticals, LLC | 12 | $211 |
| Otsuka America Pharmaceutical, Inc. | 6 | $209 |
| Akebia Therapeutics Inc | 5 | $174 |
| Amgen(2 entities) | 7 | $158 |
| Boston Scientific | 1 | $141 |
| Daiichi Sankyo Inc. | 6 | $125 |
| Ardelyx, Inc. | 5 | $121 |
| Travere Therapeutics, Inc. | 6 | $116 |
| Novartis | 4 | $104 |
| Lilly USA, LLC | 4 | $87 |
| Mallinckrodt Hospital Products Inc. | 3 | $79 |
| Veloxis Pharmaceuticals, Inc. | 2 | $65 |
| Vifor Pharma, Inc. | 3 | $63 |
| ANI Pharmaceuticals, Inc. | 3 | $53 |
| Calliditas Therapeutics US Inc. | 3 | $50 |
| GSK | 2 | $45 |
| Novo Nordisk | 2 | $43 |
| AbbVie | 2 | $37 |
| Scpharmaceuticals Inc. | 2 | $32 |
| Cormedix Inc. | 1 | $30 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Abbott | 1 | $23 |
| Sanofi | 1 | $18 |
| Shield Therapeutics Inc | 1 | $17 |
| Aurinia Pharma U.S., Inc. | 1 | $16 |
| Apellis Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$2,751 in reported general payments places this provider in the 60th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pitavastatin Calcium | 13 | $2,658 |
| Nifedipine ErNifedipine | 33 | $1,021 |
| Torsemide | 25 | $563 |
| Losartan Potassium | 24 | $208 |
| Tamsulosin Hcl | 13 | $157 |
| Lisinopril | 30 | $139 |
| Furosemide | 17 | $41 |
| Amlodipine Besylate | 14 | $33 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Houston
- Sreedhar MandayamHouston$752K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
- Namrata GoelHouston$426K
- Dana MitchellHouston$344K
- Ramachandra MalyaHouston$312K
- John ForingerHouston$215K
- Biruh WorkenehHouston$185K
- Horacio AdrogueHouston$122K
- Anand SaranathanHouston$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.